Vector Labs Ab03125-10.29 Anti-BCMA [13A4], Human Fab fragment, His-Tagged, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 13A4
Heavy Chain Modification: His-Tagged
Synonyms: CD269; BCM; TNFRSF17; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein
Amount: 100 μg
Application Codes Clone: ELISA; FC
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: Fab
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.
Specificity Statement: This antibody binds human BCMA. It acts as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. BCMA expression is highest on terminally differentiated B cells. BCMA is involved in mediating the survival of plasma cells for maintaining long-term humoral immunity. It also activates NF-kappa-B and JNK. The expression of BCMA has been linked to a number of cancers, autoimmune disorders, and infectious diseases.
Application Notes: The selection of specific binders having affinity for BCMA was done using ELISA and their affinity was determined using SPR analysis. The original Fab antibody bound human BCMA with a monovalent binding affinity of 1.8 nM. The binding of the IgG version of this antibody to membrane bound human BCMA was determined by performing flow cytometry on BCMA-expressing H929 cells and MKN45 cells. The assessment of the competition between A-APRIL and this antibody was performed on H929 cells by quantifying the binding of A-APRIL in presence of increasing concentrations of this antibody and measured by flow cytometry. This antibody was reported to not block or increase APRIL-dependent NF-κB activation and also does not block or increase BAFF-dependent NF-κB activation in vitro. This antibody was also reported to be used in the generation of antibody-drug conjugates and anti-BCMA/anti-CD3 T cell bispecific antibodies for possible immunotherapy applications in treatment of multiple myelomas (EP2953972).

Product Class:	Purified
Clone ID:	13A4
Heavy Chain Modification:	His-Tagged
Synonyms:	CD269; BCM; TNFRSF17; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein
Amount:	100 μg
Application Codes Clone:	ELISA; FC
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	Fab
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:	This antibody binds human BCMA. It acts as a receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. BCMA expression is highest on terminally differentiated B cells. BCMA is involved in mediating the survival of plasma cells for maintaining long-term humoral immunity. It also activates NF-kappa-B and JNK. The expression of BCMA has been linked to a number of cancers, autoimmune disorders, and infectious diseases.
Application Notes:	The selection of specific binders having affinity for BCMA was done using ELISA and their affinity was determined using SPR analysis. The original Fab antibody bound human BCMA with a monovalent binding affinity of 1.8 nM. The binding of the IgG version of this antibody to membrane bound human BCMA was determined by performing flow cytometry on BCMA-expressing H929 cells and MKN45 cells. The assessment of the competition between A-APRIL and this antibody was performed on H929 cells by quantifying the binding of A-APRIL in presence of increasing concentrations of this antibody and measured by flow cytometry. This antibody was reported to not block or increase APRIL-dependent NF-κB activation and also does not block or increase BAFF-dependent NF-κB activation in vitro. This antibody was also reported to be used in the generation of antibody-drug conjugates and anti-BCMA/anti-CD3 T cell bispecific antibodies for possible immunotherapy applications in treatment of multiple myelomas (EP2953972).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews